Is Recursion Pharmaceuticals (RXRX) Stock Fully Priced After Its 87% Fall?

Recursion Pharmaceuticals stock has had a rough ride over the past few years, and the current market verdict still leans expensive relative to the company’s fundamentals. For anyone looking at the recent slide in Recursion Pharmaceuticals, the key issue is whether the weak historical returns now line up with a more appealing entry point or whether pricing still builds in too much optimism.

• Over the past 5 years, Recursion Pharmaceuticals has declined about 87%, which signals that long term shareholders have absorbed heavy losses while the story the market once priced in has not yet materialised.
• The long term promise of Recursion Pharmaceuticals’ drug discovery platform can support the share price if it eventually turns into recurring revenue. However, ongoing development costs and the timing of any future cash inflows remain a major risk for valuation.
• The broader checks flag Recursion Pharmaceuticals as not a clear bargain, with a low value score of 2 suggesting the stock still leans expensive on several standard metrics.

The issue now is whether the current price of Recursion Pharmaceuticals fairly reflects the long development path ahead or still embeds expectations that are too optimistic for the risk involved.

Broaden your watchlist beyond Recursion Pharmaceuticals by scanning a curated set of beaten up but higher quality ideas in the 33 high quality undervalued stocks. These may offer a more balanced risk and valuation profile.

Is Recursion Pharmaceuticals Getting Expensive on Sales?

P/S is usually the cleaner lens for a business like Recursion Pharmaceuticals, where losses mean earnings-based ratios are less helpful. On this yardstick, the stock trades at about 30.9x trailing revenue, which is high compared with the Biotechs industry average of 12.7x and also above the peer group level of roughly 20.8x.

The fair multiple our model assigns is extremely low at about 0.0x, because the framework heavily penalises ongoing losses, execution risk and the uncertainty around turning the drug discovery platform into predictable sales. That figure is not a precise target so much as a warning flag that Recursion Pharmaceuticals appears very expensive under this approach, with a wide gap between the current P/S and what the model indicates would be justified by the present fundamentals.

On the P/S multiple, Recursion Pharmaceuticals stock appears clearly overvalued under this framework.

See what the numbers say about this price — find out in our valuation breakdown.

The Recursion Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Recursion Pharmaceuticals valuation puzzle leaves off by mapping out which combinations of future growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than it is today on the market. Each scenario links its numbers to a clear view on how Recursion Pharmaceuticals' potential, profitability and major risks could shift, which gives you something concrete to revisit as new information comes through on the Community page.

Community views on Recursion Pharmaceuticals could hardly be further apart, with one group seeing a turning point and the other seeing a cautionary tale.

Bull case: 62% undervalued

"With validated clinical data, significant milestone payments from partners like Roche, and a cash runway extending through 2027, Recursion is transitioning into a commercial-stage TechBio leader…"

Read the full Bull Case to see why Recursion Pharmaceuticals could be undervalued

Bear case: 60% overvalued

"All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! Twelve years later they have zero! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever! Nuff said…"

Read the full Bear Case to see why Recursion Pharmaceuticals could be overvalued

Do you think there's more to the story for Recursion Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Recursion Pharmaceuticals still screens as overvalued on sales based on standard market multiples, with the tailored framework heavily discounting the current loss profile and execution risk. That gap between the rich P/S ratio and what the model flags as justifiable points to expectations that remain ambitious rather than conservative. The key question for both bulls and bears is whether Recursion Pharmaceuticals can turn its drug discovery platform into meaningful, recurring revenue on a timetable that eventually aligns with the price investors are already paying today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com